Dystroglycan is a major adhesion complex composed of two subunits, alpha and beta, that undergoes extensive post-translational modifications. In particular, its alpha subunit is heavily decorated with sugars, influencing its basement membrane binding properties. An altered glycosylation of alpha-dystroglycan is at the molecular basis of muscular dystrophies defined as secondary dystroglycanopathies, that depend on malfunctioning of the enzymes in the glycosylation pathway. An increased level of transcription of the dystroglycan gene may be crucial for obtaining sufficient amounts of dystroglycan precursor substrate required for the production of the heavily glycosylated and fully functional alpha-dystroglycan molecule. Even slight differences in these transcriptional levels may exert a protective or pathogenetic effect, as discussed for the unique case of primary dystroglycanopathy so far identified (T192M), where the heart tissues are not affected by the pathology. Moreover, the N-terminal fragment of alpha-dystroglycan is also proposed to have a regulatory role in the glycosylation/maturation process. (C) 2013 Elsevier B.V. All rights reserved.
Increased levels of expression of dystroglycan may protect the heart
Brancaccio;Andrea
2013
Abstract
Dystroglycan is a major adhesion complex composed of two subunits, alpha and beta, that undergoes extensive post-translational modifications. In particular, its alpha subunit is heavily decorated with sugars, influencing its basement membrane binding properties. An altered glycosylation of alpha-dystroglycan is at the molecular basis of muscular dystrophies defined as secondary dystroglycanopathies, that depend on malfunctioning of the enzymes in the glycosylation pathway. An increased level of transcription of the dystroglycan gene may be crucial for obtaining sufficient amounts of dystroglycan precursor substrate required for the production of the heavily glycosylated and fully functional alpha-dystroglycan molecule. Even slight differences in these transcriptional levels may exert a protective or pathogenetic effect, as discussed for the unique case of primary dystroglycanopathy so far identified (T192M), where the heart tissues are not affected by the pathology. Moreover, the N-terminal fragment of alpha-dystroglycan is also proposed to have a regulatory role in the glycosylation/maturation process. (C) 2013 Elsevier B.V. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


